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Background: Mandatory co-payments attached to prescription medicines on the Irish public health 
insurance [General Medical Services (GMS)] scheme have undergone multiple iterations since their 
introduction in October 2010. To date, whilst patients’ opinions on said co-payments have been 
evaluated, the perspectives of community pharmacists and general practitioners (GPs) have not.  
Objective: To explore the involvement and perceptions of community pharmacists and GPs on this 
pharmaceutical policy change.  
Methods: A qualitative study using purposive sampling alongside snowballing recruitment was used. 
Nineteen interviews were conducted in a Southern region of Ireland. Data were analysed using the 
Framework Approach. 
Results: Three major themes emerged: 1) the withered tax-collecting pharmacist; 2) concerns and 
prescribing patterns of physicians; and 3) the co-payment system – impact and sustainability. Both 
community pharmacists and GPs accepted the theoretical concept of a co-payment on the GMS 
scheme as it prevents moral hazard. However, there were multiple references to the burden that the 
current method of co-payment collection places on community pharmacists in terms of direct 
financial loss and reductions in workplace productivity. GPs independently suggested that a co-
payment system may inhibit moral hazard by GMS patients in the utilisation of GP services. It was 
unclear to participants what evidence is guiding the GMS co-payment fee changes. 
Conclusion: Interviewees accepted the rationale for the co-payment system, but reform is 
warranted. 
Keywords: General Medical Services; Co-Payment; Framework Analysis; Health Policy; Community 
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According to the World Health Organisation (WHO), a co-payment (user charge or user fee) is 
defined as “money people are required to pay at the point of using health services covered by a third 
party such as the Government, a health insurance fund or a private insurance company”.[1]  These 
out-of-pocket fees are paid by the insured patient on many health services such as outpatient visits, 
dental care, and inpatient care and prescription medicines. There are many documented advantages 
in having a co-payment attached to prescription medicines; cost containment, moral hazard 
prevention and revenue generation.[2] Disadvantages include lower rates of drug treatment, worse 
adherence among existing users, more frequent discontinuation of therapy and increased patient 
financial responsibility.[3, 4] Co-payments are a common feature of Western health care systems.[1] 
The General Medical Services (GMS) scheme in Ireland is a tax funded, means tested, public health 
insurance scheme.[5] It provides many health benefits including inpatient and outpatient care, 
General Practitioner (GP) services and prescription medicines to those who meet the eligibility 
criteria,[6] all free at the point of access. Currently, 33% (1,565,049) of the Irish population receive 
healthcare on this scheme.[7] Patients who avail of health coverage on the GMS scheme are known 
as medical card holders. In October 2010, in an attempt to counteract rising Government 
expenditure amid a severe economic downturn post 2008, and to reduce medicine wastage, the 
Department of Health (DoH) introduced a €0.50 co-payment per prescription item, capped at €10 
monthly, for the first time for publically insured (GMS) patients.[8] Since then, the GMS prescription 
medicine co-payment, also known as the GMS levy, has undergone numerous iterations in both 
monetary value per prescription medicine and in monthly cap fee (capped after the first 10 
prescription medicines per month for each of the GMS co-payment iterations). Indeed, this levy is a 
form of taxation. Figure 1 below reveals a timeline of all recent GMS co-payment changes where in 
March 2017; the introduction of different co-payments for separate age groups was first introduced 
on this scheme. 
In the Irish context, patients were mostly accepting of the initial €0.50 co-payment with some 
reservations concerning an increased price and the way in which generated revenue would be used 
by Government.[8] This aligns with international patient perspective where most patients accept 
paying toward medication in principle.[9-11] Contemporary quantitative analysis on the GMS co-
payment increases (Figure 1) has demonstrated that the €0.50 co-payment was associated with 
reductions in adherence ranging from −2.1% to −8.3% for essential medicines and reductions in 
adherence of −2% to −9.5% for less-essential medicines.[12] The €1.50 co-payment generally 
resulted in smaller reductions in adherence to essential medicines with anti-depressant medications 
being the exception with a decrease of −10.0% after the co-payment increase.[12] For publicly 
insured families with children, a detrimental effect on health was not found from small co-payments 








The objective of the study was to retrieve insight into the engagement and opinions of experienced 
Healthcare Professionals (HCPs) on the GMS co-payment policy changes. Using the qualitative data 
collected from interviews, this manuscript aims to inform healthcare policymakers on this specific 
pharmaceutical policy as Ireland is currently in the process of attempting to deliver whole system 
reform and universal healthcare known as SláinteCare for all its citizens.[14] This study adds to the 
literature by investigating the stakeholder involvement of HCPs in co-payments attached exclusively 
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Study design, setting and sampling 
The sampling frame for this study was registered community pharmacists and GPs who had been 
consistently practising for at least six months prior to the first GMS co-payment introduction in 
October 2010 until data collection completion. Nineteen semi-structured interviews (thirteen 
community pharmacists, 6 GPs) were conducted between January 2018 and April 2019 where HCPs 
working in five different socioeconomic areas were interviewed in the province of Munster, Ireland 
(Table 1). Both community pharmacies and medical surgeries were classified into their respective 
socioeconomic classes via the Trutz Hasse Deprivation Index 2016 by electoral division.[15] HCPs 
from both independent and franchise pharmacies were included. Franchise pharmacies were 
defined those consist of several similar businesses which are corporately owned. All medical 
surgeries in this study were independently owned. Most interviews were conducted in an urban 
practice save for two marginally above average medical surgeries and one marginally above average 
community pharmacy which can be considered rural.[16] Varying socioeconomic and work place 
structures and locations were included to ensure that a broad range of thoughts and attitudes could 
be obtained from a range of social circumstances, age, gender, and work place practices. All 
interviewees declared they had no obvious bias to declare on this topic. This was asked to ensure 
that selection was not based on prior knowledge of interviewee involvement on this topic.  
Interviewing was chosen as the preferred data collection method for many reasons. First, given that 
some of the interviewees owned their own pharmacy/medical surgery, the topic of work place 
practices, medicines, and money/financial loss can be considered a sensitive subject. Secondly, focus 
group dynamics can be unpredictable where more in depth coverage, with a lower risk of social 
desirability bias, is possible when interviewing an individual.[17]. Consent form and participant 
information letters are made available (see online appendices 1, 2). Participants were sampled using 
purposive and snowball-sampling methods.[17, 18] An initial ‘core set’ of potential participants were 
identified by the research team through personal contact. These participants were then asked to 
suggest other individuals they believed could assist with the study. Participants were free to decline 
the invitation to partake but did this not happen. Once HCPs  agreed  to  be  interviewed,  the  
interviewer  explained  who  they  were,  clarified  the  aims  and objectives of the study and assured 
participants of anonymity and data confidentiality. Participants were asked for verbal and written 


















Table 1 | Distribution of practices by location and ownership status [15] 
 
Practice Location  Independent Franchise Total 
Affluent 2 1 3 
Marginally above 
average 
7 2 9 
Marginally below 
average 
2 0 2 
Disadvantaged 2 2 4 
Very Disadvantaged 1 0 1 
Total 14 5 19 
 
Data collection 
Two very similar topic guides were developed in order to achieve structured feedback from 
participants (see online appendix 3). One topic guide was targeted at the community pharmacists 
whilst the other was used when interviewing GPs. Given that both topic guides were designed to have 
a strong resemblance, data from both community pharmacists and GPs were analysed together as one 
combined HCP data pool. Both topic guides drew on existing related literature[8, 12, 19-24] and the 
professional experience of the research team. The topic guides were initially piloted with two 
pharmacists and one GP and were amended as the interviews progressed to obtain current and topical 
feedback from participants. The decision was made to exclude the pilot interviews from the analysis. 
The pharmacist topic guide underwent four iterations whereas the GP topic guide under two 
iterations. Many themes were discussed with both pharmacist and GP participants where some of 
these are highlighted in Table 2. All interviews consisted of one interviewer and one interviewee and 
were recorded and transcribed verbatim using two methods of audio recording: a Dictaphone (Sony 
IC Recorder ICD-PX240) and a mobile phone device (Samsung Galaxy S6 SM-G920F). Interviews took 
place in the workplace office of the HCP being interviewed allowing for a quiet and confidential space. 
Interviews ranged in time from roughly 7 minutes to 30 minutes. A field diary was brought to each 
interview to record noteworthy observations. 
The study did not have a target sample size; rather it aimed to recruit participants until data saturation 
of key themes emerged. During data collection, before considering further participation recruitment, 
preliminary data analysis was conducted to highlight when researchers were approaching data 
saturation. In addition, the Francis et al. method was intended to be used to determine data 
saturation.[25] This method involves identifying an initial analysis sample size and then defining a 








which no new themes will emerge. It was agreed that data saturation had been reached after 16 
interviews with no new themes emerging in the additional three interviews.   
Table 2 | Themes discussed in interviews 
 
Positive/negative aspects of co-
payment? 
What are your thoughts on the co-payment attached to 
prescription medicines? 
Influence of co-payments on your 
practices and procedures? 
Has the co-payment influenced your practice or procedures 
in the work place? 
Co-payment retrieval? How easy or difficult is it to retrieve the co-payment? 
Patients’ perception of co-
payment? How do you think patients perceive paying the co-payment?  
Financial loss? Have you suffered financial loss from patients not paying? 
Medicine utilisation? Do you think the co-payment has influenced patients’ utilisation of medicines? 
Impact of co-payments on GPs 
prescribing habits? 
Has the co-payment changed the way you prescribe or 
influence the amount of prescriptions you issue? 
Future status of co-
payment/policy suggestions? 
What do you think the future holds for the co-payment? 
Should it be increased/decreased/abolished? 
 
Analysis  
The framework method was used to identify themes emerging from the data obtained and was chosen 
because of its relevance in policy change and detailed format in comparison to regular thematic 
analysis.[17, 26] The framework method contained seven key stages that allowed for the 
categorisation and organisation of the large amounts of data to help develop underlying themes and 
emerging phenomena. These seven stages consisted of i) transcription ii) familiarisation with the 
interview iii) coding iv) developing a working analytical framework v) applying the analytical 
framework vi) charting data into the framework matrix and vii) data interpretation and mapping.[27, 
28] The framework constructed throughout this process was continually amended and “tested for fit”. 
Language was seldom altered in an attempt to retain original meaning and context. The analysis was 
interpretative recognising the interaction between the researcher and the data.  
The data were managed through NVivo12 Plus, QSR International software.[29] Data analysis was 
conducted by GOB, a research pharmacist undertaking a clinical pharmacy PhD. Intercoder reliability 
was used at early stages of the project to ensure a high rate of intracoder reliability on subsequent 
manuscript data analysis. A sample of four random manuscripts were coded and indexed by BOF. At 
the time of data collection, BOF was an undergraduate pharmacy student. Both GOB and BOF 
discussed arising differences in this process to ameliorate the accuracy of the thematic framework and 
the application of the framework to subsequent transcripts. Some disagreements in coding arose. The  








phenomenon  e.g.,  dissatisfaction with Government  and  anger towards the Irish Health Service 
Executive (HSE). Through  discussion,  these  indexing  discrepancies  were resolved.[30] Both GOB and 
BOF had undertaken qualitative data analysis training courses prior to data collection. 
Ethics  
Ethical approval was sought from and granted by the Clinical Research Committee of the Cork 
Teaching Hospitals prior to study commencement. The consolidated criteria for reporting qualitative 




Nineteen HCPs were interviewed in total each with varying experience (Table 3). The Framework 
approach produced three main themes where each are elaborated on below. In the reported analysis, 
participant pseudonyms were created to provide information about: practice ownership [Independent 
(‘Indep’) or Franchise (‘Fran’); community pharmacist participant number (‘CP1’) or general 





































Table 3 | Characteristics of interviewees 
 
Sex Male 13 
Female 6 

















Employment status Full time 14 
Part time 5 










The withered tax-collecting pharmacist  
It was unanimously accepted that although the current co-payment system has advantages pertaining 
to cost containment and waste reduction, the pharmacist is just one party who suffers from its 
consequences “I didn’t study for five years in order to become an organ of revenue collection for the 
Government, it is outside the terms and conditions of my role and it’s certainly outside the terms and 
conditions of my contract with the HSE to raise money for the revenue commissioners” IndepCP11. 
Pharmacists can occasionally find themselves in “dangerous situations” FranCP12 upon co-payment 
retrieval, and in scenarios whereby they must supply the medicine without retrieving the co-payment 
“you’re spending your time trying to look after the best interests of the patient and sometimes the best 
interests of the patient is I need you to take these medications so I'm going to have to sacrifice. My 
duty of care to you as a patient trumps my duty of care to the state to collect a tax for them. So 
therefore the net loser in that transaction is the pharmacist who essentially is now working for free” 
IndepCP11. 
Pharmacists also expressed a loss of workplace productivity by collecting the co-payment “if it’s simply 








day, your efficiency is gone down dramatically and that's time that’s taken from something” 
IndepCP05. Pharmacists too experience patient disgruntlement at the point of transaction “I think 
there is still a lack of understanding that it’s a Government levy as opposed to a personal, pharmacist 
into-the-pocket levy. That is something that is still an area of confusion, even now” IndepCP02. There 
was an emergent consensus that they should not bear the financial loss if a patient cannot/will not 
pay. When a pharmacist supplies a medicine to a patient who cannot/will not pay, the primary care 
reimbursement services (PCRS) still deduct this co-payment tax/levy from the pharmacist. In addition, 
as there is a maximum monthly co-payment cap for households, if family members are not recognised 
as one household unit on the electronic PCRS system, the pharmacists bear the financial deficit. As a 
result, pharmacists have reported large financial losses “Tens of thousands of euro for reasons of non-
payment, but also for reasons of families weren’t linked properly on the PCRS database. Those are 
probably the two most common causes of a deficit in what I should have taken in, what the State 
deducted from me and what I was able to take in” IndepCP11.  
Pharmacists note that a proportion of GMS patients acknowledge the value of having the co-payment 
attached to their medicines “…….. they think they’re getting good value for money and that it’s a good 
thing for the country…” FranCP13. However the risk to patient safety which arises from having a co-
payment system was recognised by community pharmacists:  “From the pharmacy perspective it has 
introduced extra administrative issues, …… therefore has caused a danger, in my view, to patient safety 
because if you are having to talk to Mrs. Murphy about a blasted prescription charge, when you really 
should be concentrating on the prescription and the dose and the interactions and all of this…….” 
IndepCP05. 
 
The co-payment system – impact and sustainability 
Before the introduction of the co-payment on the GMS, medication stockpiling and wastage was noted 
as a prominent feature by both pharmacists and GPs. “I did a house call and I asked the lady, ‘Oh, 
where do you keep your tablets?’  In under the stairs I removed at least 10 Tesco® plastic shopping 
bags full of unused medication. They were stockpiled in the thing.  … There was bags of them…..going 
back like 10 years…….  There was like tens of thousands of tablets that she wasn’t taking” IndepGP02. 
Medication waste seems to be ongoing but not at the level that it once straddled. “unfortunately, we 
see it particularly again when patients pass away, the big black bag of unused medication, I don’t 
believe the black bags have got any smaller since the October 2010, ‘til January 2018” FranCP08. 
The consensus from interviewees is that the co-payment system influences medicine utilisation and 
adherence rates. “The PRN stuff would be the first to go, so if there are items they genuinely don’t 
need, they would be the ones that would first go” IndepCP04. However, some pharmacists advocate 
“the co-payment certainly has disimproved compliance for certain groups of people.  So I think in terms 
of benefits to how people take their medicine, the people that come back regularly for medication, 
when there was no 2.50 levy or no 50 cent levy, would generally be compliant.  There are people that 
now choose to come back regularly for certain items and not for others or they will take items, run 








beneficial when a patient has to make a decision as to whether their blood pressure is more important 
than their cholesterol. You don’t feel your blood pressure being high. You don’t feel your cholesterol 
level being high. They would be always the easier ones to drop” FranCP13. This is worrying as it means 
patients have to choose between which essential medications to take which poses a big threat to 
patient safety. This feature is also observed amongst patients without medical cards how much more 
they pay for medication “….... It’s the poor private paying patient…. They’ll come to you and they’ll say, 
‘Look, ok, that blood pressure tablet’ and it might be for example an ACE inhibitor, ‘what’s the cheapest 
one I can get of that?” IndepGP02.  
Most HCPs agree that the co-payment system is a good tool to deter moral hazard but not to generate 
revenue “If it was 50 cents like it had been initially, then there’s an understanding of why it’s there. 
Going to 2.50 in 2013 was the one that impacted most…… So, 2.50 would probably be the straw that 
breaks the camel’s back in terms of the amount that patients are going to pay. Being at the 50 cent 
charge was the one to leave it at.  We understood the policy behind it, you know.  Trying to increase it 
up to generate revenue just doesn’t make sense from a health point of view” FranCP13. In fact, HCPs 
recommend eligible patients with a long-term illness (LTI), as classified by the HSE, to switch to the LTI 
scheme where there is no co-payment on prescription medicines i.e. GMS co-payment (tax) avoidance 
“we’ve been migrating them (eligible medical card patients) over to the LTI scheme” IndepCP02 and 
“if you go online to the Diabetes Ireland website, they’ll tell you, ‘If you’ve a medical card, make sure 
you get a long-term illness‘. So they’re actually telling people to avoid the levy” IndepCP11.  However, 
some participants described the unfairness of this scheme which is not means tested “Why should a 
long term illness patient, you can have a retired High Court judge, a retired Taoiseach who might have 
Type 2 diabetes availing of all those levies for their cardiovascular medicines, their statins, their aspirin 
all free of charge, not even a levy paid and somebody with mental health difficulties who could be in 
very poor social circumstances, on social welfare, having to pay €2.  That is grossly unfair” IndepCP11.  
Both pharmacists and GPs want the system to remain in place “if Sinn Féin (An Irish left-wing Irish 
republican political party) get into Government, they might promise to abolish it (the GMS co-
payment) as a great stroke to the people, but I firmly believe that the people in the medical card 
system get an excellent service for nothing and that the co-payment is a very small little contribution 
to the exchequer and it’s tiny in the overall scheme of things” IndepGP03. Notwithstanding this 
perspective, it was interesting to note that some interviewees suggest that the co-payment system 
“should be means tested” in order to reduce health inequalities IndepGP05. As well as GPs who 
believe that “GP unions should be involved in co-payment policy because it does affect the workload” 
IndepGP01, pharmacists want to be heavily involved in the co-payment policy. They have many 
suggestions for co-payment policy improvement “The fee should certainly be decreased down back 
to 50 cent, but with a greater emphasis then on exemptions so that there could be specific patients 
who shouldn’t have to pay, a greater cohort of patients that shouldn’t have to pay.  So say for 
example, if a patient is diagnosed with cancer and is entitled to a medical card, then they should be 









Concerns and prescribing patterns of physicians 
GPs report that the co-payment has fine-tuned their prescribing habits “has made me a little bit more 
conscious of what I prescribe for patients in that are they going to take it?  Are they going to pay 2.50?  
Ok, it doesn’t sound like a lot, but do you know, whatever it is, it’s nearly €30 a year, whatever, per 
item and patients on a social welfare budget, that’s an awful lot of money.  So it makes me a little bit 
more conscious of it” IndepGP06. In addition, the co-payment seems to create additional dialogue in 
the medical surgery “Maybe I get into the conversation of what they need this month more so than I 
would have in the past” IndepGP05. It appears that having a co-payment system on medicines may 
result in a more customised prescription for the patient. 
An unforeseen concept that arose was the potential introduction of a co-payment system attached to 
GP surgery visits for medical card holders. Medical card holders currently avail of unlimited GP surgery 
visits free at the point of access. This was first alluded to by a pharmacist in the early stages of data 
collection phase “…if the patient had a medical card and had to pay €5 to see the doctor or €10 to see 
the doctor, they’d see something then….”FranCP09. When interviewing subsequently commenced 
with GPs, this idea was something that materialised through many indirect quotations where one GP 
summarised the opinion concisely “I think we are heading towards free GP care and free medication 
which I don’t necessarily agree with……GPs would be in favour of advocating for co-payment both for 
medication and attendance of surgery visits” IndepGP06. As there is an ongoing general practice crisis 
with over 26 communities without a GP,[32] the potential introduction of a co-payment system 
attached to GP surgery visits for medical card holders could prevent unnecessary consultations thus 
maximising current GP performance. 
   
Discussion 
This exploratory study provides a range of insights into HCP views on GMS pharmaceutical policy 
change over the last decade. What was evident from this analysis is that all participants, in some 
manner, think the GMS prescription medicine co-payment system is a good idea. However, the 
pharmacist cohort state they do not want to be an “organ of revenue collection” for the GMS co-
payment. This tends to result in various losses of productivity that are not remunerated. Indeed, this 
financial loss is much more than not being able to retrieve the levy. It is felt in the form of loss of 
staff productivity where administration workload and procedures have dramatically increased. In 
addition, it appears that the current information technology (IT) systems are not fit for purpose with 
respect to GMS co-payment retrieval. Financial losses suffered by pharmacists are also brought 
about by the absence of family unit linking on IT software systems in the pharmacy setting. For 
example, one family might pay the GMS co-payment cap of €20 for medicines per calendar month. 
However, because of poor IT systems communication, it not is recognised that the individuals in the 
family who form a family unit all fall under the GMS co-payment cap, therefore the PCRS will deduct 
the €20 co-payment cap for each individual instead of for the family unit per calendar month 
resulting in financial loss for the pharmacist. This is something which needs to be rectified by the 








payment retrieval transaction. As the GMS co-payment is a tax, it could be argued that patients 
should deal directly with the tax collector/revenue commissioner regarding the payment of this levy 
as is done with other forms of taxation. Alternatively, pharmacists may be remunerated for co-
payment collection, or at the very least, not financially penalised when they are unsuccessful at co-
payment retrieval as is currently the case. The literature is sparse on this topic and further research 
is required. 
Like in some Western European countries,[33, 34] publically insured patients in Ireland including 
those aged over 70, those under 6 years and carers avail of GP visits, free at the point of access.[13] 
An unexpected finding from this study was that GPs have suggested that a similar co-payment policy 
be attached to GMS patient-physician consultations that occur in their medical surgeries to prevent 
unnecessary overuse of this free saturated service.[32] This finding indicates that overburdened GPs 
are aware of the concept of moral hazard and are proposing potential solutions on how to handle 
increasing demand on healthcare services. More European countries are attempting to or already 
have put policies like this in place for publically insured patients.[34] For instance, patients aged 20 
years or older on the public health insurance scheme in Sweden pay a co-payment of approximately 
€10 to a front desk receptionist per primary care physician visit.[35] Although subtleties exist across 
different Swedish regions, in general, the co-payment is seen as an income to the primary care 
centre, and this will be taken into account when distributing funds from the regional government to 
each care centre. In the Czech Republic, the evidence reveals no overall effect of doctor visit co-
payments on the number of children's doctor visits.[36] However, before such a policy could be 
implemented in Ireland, the fee for this co-payment would have to be carefully selected. Some 
research has found that prescription medicine co-payment could potentially affect the number of 
doctor visits [37] especially higher co-payment fees which may reduce healthcare service utilisation 
mainly because of a demand reduction of poorer patients.[38] Thus, more in-depth investigation is 
required to determine the optimal co-payment fee per patient-physician consultation in primary 
care and how best this fee could be retrieved in practice.   
It was unclear to participants what evidence is guiding these GMS co-payment fee changes. GMS co-
payment changes are usually announced around general election time by contesting politicians or on 
national budget day by Government officials, unaccompanied by any solid evidence of what impact 
such increases or decreases can have. Previous iterations have yielded reductions in adherence to 
essential medicines, including anti-depressant medications with a large decrease of −10.0%.[12] 
Reduction in the use of essential medicines results in worsening patient adherence, leading to 
poorer health outcomes and increased usage of health services.[39-41]. This is a healthcare policy 
not a revenue generating exercise.  If Ireland’s ten-year Sláintecare plan for whole health system 
reform through political consensus is going to be implemented successfully, then healthcare 
policymakers need stakeholder buy-in to ameliorate existing pharmaceutical polices like this. In this 
study, both GP and pharmacy unions have expressed interest to be more involved in the policy 
formation stages, not the post-implementation stages. Sláintecare represents a unique opportunity 
for all key stakeholders including policymakers, HCPs and patients to collaborate and provide input 








It appears that GMS co-payment policy is having a ripple effect on the LTI pharmaceutical policy. 
HCPs and others have recommended GMS patients with an “eligible” LTI, as classified by the HSE, to 
avoid paying the co-payment by switching to the non-means tested LTI scheme. Although the 
dispensing fees paid to community pharmacies for both GMS and LTI reimbursement schemes are 
equivalent,[7] this switching of schemes creates extra administrative burden elsewhere in the health 
system. It results in patients straddling two schemes at pharmacy level. Patients get their LTI related 
medicines free of charge while concomitantly using the GMS scheme to retrieve their non-LTI 
related medicines. This lead to discussion on the complexity of the whole medicine reimbursement 
system in Ireland and the associated co-payments where over 20 such schemes exist in the primary, 
secondary and tertiary care settings [7, 42] One HCP summarised the medicine reimbursement and 
the GMS co-payment system in Ireland quite nicely “Even saying this out loud sounds absolutely 
ridiculous, you know, because if you landed from Mars and you said, ‘I've got an idea for a tax(co-
payment fee)’, nobody would think that this was credible”  IndepCP11.  
Limitations 
This study is not without its limitations. Access to the total number of patients that each medical 
practice serves, and which proportion of those patients were GMS patients, was unattainable. Such 
information could have been useful in drawing conclusions between the socioeconomic differences 
of different patient groups. Recruitment of participants was conducted between January 2018 and 
April 2019. Arguably, the data collection could process could have been quicker but the primary 
researcher (GOB) was involved in multiple ongoing research projects at the time. 
As mentioned  in  the  methods  section,  an initial core set  “convenience sample” was used for data 
collection. Concerns regarding selection bias  in  recruitment  were  mediated  by  the  fact that  the  
sample  obtained  was  representative  of  the  practising HCP population. Pilot interviews were 
excluded from the data analysis. Although valid interviews, the interviewers felt their interviewing 
techniques at this early stage may have influenced participants’ responses. Securing interviews with 
GPs proved more difficult than with pharmacists which, resulted in disproportionate numbers 
between the groups. However, an approximately equal amount of pharmacist quotations and GP 
quotations are reported in the results section of this paper in an attempt to further minimise 
selection bias.  
The main researcher  is  a research  pharmacist  and  the  second interviewer  was  a  final  year  
pharmacy  student at the time of data collection,  thus there was a possibility that participants gave 
socially desirable responses.  This bias was  difficult  to  eliminate  as  the  research team felt  that by 
disclosing the  researchers’  backgrounds  to  interviewees  an  element  of  professionalism could be  
introduced  into  the  interviews.  However given that participants were also HCPs practising much 
longer than both interviewers, it  may  be taken that the interviewers established a solid rapport 
with participants and socially desirable answers did not feature dominantly in the results. 
From 1st April 2019, around the same time data collection had ceased, for people aged 70 years and 
over, the prescription charge decreased to €1.50 per GMS prescription item, up to a maximum of 








remained at €2.00, up to a maximum of €20 per month per person or family. Therefore, it is believed 
that this co-payment change did not affect the study results. Furthermore, in October 2019, the 
Department of Finance announced that a €0.50 reduction per GMS prescription item for all medical 
card holders will come into effect in July 2020.[44] This research was originally intended to be part of 
a mixed methods study where the overall aim was to determine the impact of altering prescription 
charges on patient adherence to medicines on the public GMS scheme in Ireland. The quantitative 
study planned to measure changes in adherence in essential and less-essential medicines[45, 46] pre 
and post GMS co-payment changes. However, access to national PCRS data [47] required for said 




The GMS co-payment has undergone many various iterations in recent times. Previous studies have 
examined its impact and sought to retrieve “the optimal co-payment” which prevents medicine 
wastage and acts as a revenue stream.[8, 12] However, this study too implies that there is no optimal 
co-payment fee considered by patients and by HCPs. GPs and pharmacists did seem to favour a lower 
amount. Perhaps healthcare policymakers should formally evaluate its value every few years to see if 
change is warranted. The Czech Republic lead by example in this field as they seem to monitor and 
update their co-payment system quite regularly. Indeed, this study comes at an important time as the 
Irish Healthcare system undergoes major political, economic and health policy reform under the 
Sláintecare policy.[14] Through political concord, the Irish Government are aiming to reorient the 
health system ‘towards integrated primary and community care, consistent with the highest quality 
of patient safety in as short a time-frame as possible’.[48, 49] This study has provided a platform for 
experienced primary care HCPs to express their views and accounts of the Irish GMS co-payment 
system. For the most part, HCPs agree that there is merit to having a nominal charge attached to 
prescription medicines on the GMS scheme. However, participants have highlighted outstanding 
issues that need to be optimised to ameliorate primary healthcare practices and procedures.[50, 51] 
With respect to Lewin's basic change theory model of unfreezing, changing, and refreezing,[52] 
healthcare policymakers implementing the ten-year Sláintecare reform can bypass the unfreezing 
stage of this contemporary pharmaceutical policy. Both pharmacy and general practitioner 
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A qualitative analysis of the healthcare professional stakeholder involvement in 
pharmaceutical policy change in Ireland 
 
I                                                    declare that information about this research 
project has been given to me and that I understand the purpose, methods, risk and benefits of 
participating in this study.  
I am aware that participating is voluntary and that I can withdraw my participation at any time with 
no negative impact on my professional status.  
I give permission for my responses in the interview to be audio-recorded and that anonymity will be 
ensured by disguising my identity.  
I understand that disguised extracts from what I say may be quoted in the thesis and any subsequent 
publications.  
I agree that I have received a copy of this Consent Form and a copy of the Information Letter. 
I hereby give my informed consent to participate in the research study. 
 
 
Participant Signature                                                Date 
 
Would you like a copy of the Interview Transcript?                  YES               NO    
 











Participant information letter 
 
A qualitative analysis of the healthcare professional stakeholder involvement in 
pharmaceutical policy change in Ireland 
You are being invited to take part in a research project that is being conducted at the University College 
X.  
Before you decide whether or not you wish to participate you should read the information provided 
below carefully, and you are free to discuss it with your family, friends or colleagues. You should clearly 
understand the risks and benefits of participating in this study so that you can make a decision that is 
right for you. Take time to ask questions – do not feel rushed or under any obligation to make a hasty 
judgment.  
You have the right to withdraw your participation at any time (before, during and after the study) for 
whatever reason without having to justify your decision and with no negative impact for you. Your 
data will then be excluded from the study results. 
Why is this study conducted? 
Co-payment policies on the General Medical Services (GMS) scheme have existed since 2010 and have 
gone through multiple iterations, starting at €0.50 in October 2010 and reduced to €2 in January 2018. 
The involvement of the Healthcare Professionals (HCPs) such as General Practitioners (GPs) and 
Pharmacists in such pharmaceutical policy changes on the GMS scheme has not been evaluated. As 
part of his PhD, X wants to gather feedback on the perceptions and challenges experienced by HCPs 
resulting from the GMS co-payment changes. For example, are co-payment changes creating 
additional administrative burden for HCPs? Have altering co-payments influenced GPs’ prescribing 
patterns? How have pharmacists handled the implementation of this policy? What happens if patients 
cannot afford these prescription medicine co-payments? This study seeks to retrieve qualitative data 
on HCP stakeholder involvement for all existing co-payment alterations in the Irish context. 
Why have you been asked to participate? 
You have been asked because you are a Healthcare Professional currently working in a GP practice or 
a community pharmacy in the Republic of Ireland.  
What will your participation involve? 
Your participation will involve a 30-minute (maximum) interview about matters relating to your 








pharmacist, will ask questions as the session progress. A small amount of extra time will be allowed 
for explaining the aims of the study and your questions about the study.  
Will your participation be kept confidential? 
Yes, all information will be treated in a confidential manner and your participation is anonymous. The 
interview will be audio recorded so that it can be transcribed afterwards. Your name will not be 
recorded on any information which is collected about you. Instead you will be provided with a unique 
code. The only person with access to the code will be X. The results of the study will be included in X’s 
PhD thesis but there will be no way of identifying you from these results. The results will be seen by 
X’s supervisors, a second marker and an external examiner, again these will be anonymous. The thesis 
may be read by future students. The study may be presented at scientific conferences and/or 
published in an academic journal.  
The audio recording will be erased once the interview has been transcribed. Transcripts will be stored 
in a protected manner for 5 years, after which they will be destroyed in line with University College X 
confidential waste destruction guidelines. 
What are the possible benefits of participating? 
Your contribution to this study will be used to reveal how HCPs have previously dealt and are currently 
dealing with these GMS co-payment policy changes since its inception in 2010. X hopes to publish such 
findings that may influence future healthcare policymaking decisions to the benefit of the HCP and 
patient. 
Are there any risks of participation? 
We do not think that participation in this study will have any negative effect on you.  
Further information 
Approval has been granted to do this study by the Clinical Research Ethics Committee of the Cork 
Teaching Hospitals.  
If you would like a copy of the results, please let X know. 
If you need any further information, do not hesitate to contact the primary researcher, X, by telephone 
X or by email to X or email the supervisor of the project, Professor Y by Y (Telephone:Y). 
Thank you for taking the time to read this information sheet. If you agree to take part in the study, 
please sign the consent form overleaf.  
 
Kind Regards,  
X 









Pharmacist Topic Guide 
Interviewing practising Irish primary healthcare professionals about their opinions, perceptions, 
challenges and experience of the GMS co-payment from inception to current day. 
Before we start, I just want to check that you are still happy for this interview to be recorded and 
that you know we can stop at any time.  
 
I would like to thank you for agreeing to participate in this interview and stress that everything said 
here today is completely confidential. Your name will not appear on any documents or recording 
discs and I personally will anonymise the transcript from this interview, and will ensure that no one 
else will be identifiable either.  
 
These interviews are part of a study I am conducting for my PhD. The aim of the study is to gain an 
understanding of the perceptions and challenges experienced by healthcare professionals from the 
various GMS co-payment iterations since 2010. 
 
There are no right or no wrong answers to these questions. 
The interview will probably last between 10-30 minutes.  




• Address of Pharmacy? Independent or Franchise Pharmacy? 
• Gender? 
• Number of years practising in community Pharmacy? 
• Full-time/Part-time? 
• Year received pharmaceutical society of Ireland (PSI) number? 
• Do you have any obvious biases to declare on this topic? 
In Supplementary material Figure 1 presented to you in the information leaflet, you can see the GMS 
co-payment has undergone various iterations since its initial introduction in 2010. As you have been 
practising throughout these changes, I am interested to learn about your experiences in considering 
these policy changes in your routine clinical practice.  
Version 4  
 
1) What are your own thoughts on the GMS co-payment attached to prescription medicines? 
 
• Positive aspects/negative aspects? 
• Do you know why it was initially brought in and its impact to date? 








2) How have co-payments influenced your practice and procedures in the Pharmacy, if at all? 
• Have they changed the way you and the Pharmacy staff work, if so, how? 
3) How easy or difficult is it to retrieve co-payments from patients?  
• What happens if a patient cannot pay? Do you supply the medicine anyway? 
• Have you a procedure in place for patients who cannot pay? 
• Have you encountered awkward situations when a patient cannot pay? 
• Have you suffered financial loss because of patients not paying? 
4) In your opinion, have co-payments presented an administrative burden to you/your practice?  
• Have you noticed/recommended eligible patients to switch to the long-term illness (LTI) 
scheme to avoid paying the co-payment?  
5) How do you think GMS patients perceive paying the co-payment attached to their prescription 
medicines? 
• Do you think the co-payments are reasonably or unfairly priced for GMS patients?  
6) Do you think co-payments have influenced patients’ utilisation of medicines?  
• Increase/decrease in patients picking up their medicines?  
• Are there particular types of medicines affected more by the GMS co-payment changes? 
7) Looking at Figure 1, would you have regarded any one of these GMS co-payment changes to be 
more influential or impactful than the others? 
• Effect on patient picking up medication 
• More difficult to retrieve the co-payment from the patient upon being increased? 
8) Have you noticed any changes to the prescribing patterns of physicians since the introduction and 
changes in the GMS co-payment?  
• Any issues/concerns arising from GPs concerning GMS co-payments?  
• An increase in generic prescribing since the beginning of the co-payment? 
9) What do you think the future holds for the GMS co-payment?  
• Should the co-payment be increased, decreased or abolished? 
• Do you think the previous GMS co-payment changes were evidence-based? 
• How should Pharmacists/representative bodies be involved in this policy, if it all?  
 









General Practitioner (GP) Topic Guide 
Interviewing practising Irish primary healthcare professionals about their opinions, 
perceptions and experience of the GMS co-payment from inception to current day 
Before we start, I just want to check that you are still happy for this interview to be 
recorded and that you know we can stop at any time.  
 
I would like to thank you for agreeing to participate in this interview and stress that 
everything said here today is completely confidential. Your name will not appear on any 
documents or recording discs and I personally will anonymise the transcript from this 
interview, and will ensure that no one else will be identifiable either.  
 
There will not be any consequences to what you tell me and there will be no blame 
attributed to you or anyone else.  
 
These interviews are part of my PhD There are no right or no wrong answers to these 
questions, just give as much detail as you can. It will probably last between 10-30 minutes.  




• Address of GP practice? Independent or medical centre practice? 
• Gender? 
• Number of years practising as a GP? 
• Full-time/Part-time? 
• Year received Irish medical council (IMC) number? 
• Do you have any obvious biases to declare on this topic? 
 
In Supplementary material Figure 1 presented to you in the information leaflet, you can see 
the GMS co-payment has undergone various iterations since its initial introduction in 2010. 
As you have been practising throughout these changes, please answer the following 
questions with respect to this. 
Version 2  
1) What are your own thoughts on the GMS prescription medicine co-payments? 
• Positive aspects/negative aspects? 
• Do you know why it was initially brought in and its impact to date? 









2) How have co-payments influenced your practice and procedures as a GP, if it all? 
• Have they changed the way you prescribe, if so, how? 
• Have they influenced the amount of prescriptions you issue, if so, how? 
• What happens if you know a patient cannot pay? Do you still prescribe the medicine? 
• Have you noticed/recommended eligible patients to switch to the long-term illness (LTI) 
scheme to avoid paying the GMS co-payment? 
 
3) How do you think GMS patients perceive paying the co-payment attached to their prescription 
medicines? 
• Do you think the co-payments are reasonably or unfairly priced for GMS patients?  
4) In your opinion, are GMS co-payments effective at preventing patients from collecting medicines 
they actually do not require? 
• Yes/no – Why? 
5) In what way, if any, do you think co-payments have influenced patients’ utilisation of medicines?  
• An increase in patients asking you to prescribe/deprescribe certain medicines 
• A decrease in patients asking you to prescribe/deprescribe certain medicines 
 
6) In your opinion, are there particular types of medicines affected more by the GMS co-payment 
changes? 
7) Looking at Figure 1, would you have regarded any one of these GMS co-payment changes to be 
more influential or impactful than the others? 
• Effect of patient asking you to presecribe/deprescribe certain medicines 
• Patient expressing concern to you on co-payment changes 
 
8) Have you encountered any issues or concerns from patients concerning GMS co-payments that 
they may have experienced when collecting prescription medicines at their pharmacy?  
9) Have you encountered any issues or concerns from pharmacists concerning GMS co-payments 
that they may have experienced when serving patients in the pharmacy? 
10) What do you think the future holds for the GMS co-payment?  
• Should it be increased, decreased or abolished?  
• Do you think the previous GMS co-payment changes were evidence-based? 
• What advice have you for policymakers on it? Should GP representative bodies be involved?          
 


















        INCREASE      INCREASE                            DECREASE                              DECREASE 
    
€2.50->€2.00 
decreased for 




























Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist [31] 
 
Developed from: 
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-
item checklist for interviews and focus groups. International Journal for Quality in Health Care. 2007. 
Volume 19, Number 6: pp. 349 – 357  
 
YOU MUST PROVIDE A RESPONSE FOR ALL ITEMS. ENTER N/A IF NOT APPLICABLE 
 
No.  Item  
 
Guide questions/description Reported on Page # 
Domain 1: Research team 
and reflexivity  
  
Personal Characteristics    
1. Interviewer/facilitator Which author/s conducted the interview or 
focus group?  
GOB and BOF  
2. Credentials What were the researcher’s credentials? E.g. 









4. Gender Was the researcher male or female?  Male 
5. Experience and training What experience or training did the researcher 
have?  




Group, May 2018, 
University of Oxford 
Relationship with participants    
6. Relationship established Was a relationship established prior to study 
commencement?  
No 
7. Participant knowledge of 
the interviewer  
What did the participants know about the 
researcher? e.g. personal goals, reasons for 
doing the research  
Based on participant 
information letter 
provided 
8. Interviewer characteristics What characteristics were reported about the 
interviewer/facilitator? e.g. Bias, assumptions, 












Domain 2: study design    
Theoretical framework    
9. Methodological orientation 
and Theory  
What methodological orientation was stated 
to underpin the study? e.g. grounded theory, 
discourse analysis, ethnography, 




Participant selection    
10. Sampling How were participants selected? e.g. 




11. Method of approach How were participants approached? e.g. face-
to-face, telephone, mail, email  
Email, phone, face-
to-face 
12. Sample size How many participants were in the study?  19 
13. Non-participation How many people refused to participate or 
dropped out? Reasons?  
0 
Setting   
14. Setting of data collection Where was the data collected? e.g. home, 




15. Presence of non-
participants 
Was anyone else present besides the 
participants and researchers?  
No 
16. Description of sample What are the important characteristics of the 




the introduction of 
the co-payment in 
2010 to end of study 
date 
Data collection    
17. Interview guide Were questions, prompts, guides provided by 
the authors? Was it pilot tested?  
Questions were 
based on the topic 
guides used 
18. Repeat interviews Were repeat interviews carried out? If yes, 
how many?  
N/A 
19. Audio/visual recording Did the research use audio or visual recording 
to collect the data?  
Two methods of 
audio recording 









20. Field notes Were field notes made during and/or after the 
interview or focus group? 
Notes were added 
to a field diary 
immediately after 
the interview 
21. Duration What was the duration of the interviews or 
focus group?  
7 - 30 minutes 
22. Data saturation Was data saturation discussed?  Yes  (Francis 
method[25]) 
23. Transcripts returned Were transcripts returned to participants for 
comment and/or correction?  
Optional if 
participants 
required – choice 
presented on the 
consent form 
Domain 3: analysis and 
findings  
  
Data analysis    
24. Number of data coders How many data coders coded the data?  One primary coder 





25. Description of the coding 
tree 
Did authors provide a description of the coding 
tree?  
Yes 
26. Derivation of themes Were themes identified in advance or derived 
from the data?  
Both deductive and 
inductive themes 
are presented 
27. Software What software, if applicable, was used to 
manage the data?  
NVivo 12 Plus - QSR 
International 
28. Participant checking Did participants provide feedback on the 
findings?  
No 
Reporting    
29. Quotations presented Were participant quotations presented to 
illustrate the themes/findings? Was each 
quotation identified? e.g. participant number  
Yes 
30. Data and findings 
consistent 
Was there consistency between the data 
presented and the findings?  
Yes 
31. Clarity of major themes Were major themes clearly presented in the 
findings?  
Yes 
32. Clarity of minor themes Is there a description of diverse cases or 

















A qualitative analysis of the healthcare professional stakeholder involvement in 
pharmaceutical policy change in Ireland 
 
I                                                    declare that information about this research 
project has been given to me and that I understand the purpose, methods, risk and benefits of 
participating in this study.  
I am aware that participating is voluntary and that I can withdraw my participation at any time with 
no negative impact on my professional status.  
I give permission for my responses in the interview to be audio-recorded and that anonymity will be 
ensured by disguising my identity.  
I understand that disguised extracts from what I say may be quoted in the thesis and any subsequent 
publications.  
I agree that I have received a copy of this Consent Form and a copy of the Information Letter. 
I hereby give my informed consent to participate in the research study. 
 
 
Participant Signature                                                Date 
 
Would you like a copy of the Interview Transcript?                  YES               NO    
 











Participant information letter 
 
A qualitative analysis of the healthcare professional stakeholder involvement in 
pharmaceutical policy change in Ireland 
You are being invited to take part in a research project that is being conducted at the University College 
X.  
Before you decide whether or not you wish to participate you should read the information provided 
below carefully, and you are free to discuss it with your family, friends or colleagues. You should clearly 
understand the risks and benefits of participating in this study so that you can make a decision that is 
right for you. Take time to ask questions – do not feel rushed or under any obligation to make a hasty 
judgment.  
You have the right to withdraw your participation at any time (before, during and after the study) for 
whatever reason without having to justify your decision and with no negative impact for you. Your 
data will then be excluded from the study results. 
Why is this study conducted? 
Co-payment policies on the General Medical Services (GMS) scheme have existed since 2010 and have 
gone through multiple iterations, starting at €0.50 in October 2010 and reduced to €2 in January 2018. 
The involvement of the Healthcare Professionals (HCPs) such as General Practitioners (GPs) and 
Pharmacists in such pharmaceutical policy changes on the GMS scheme has not been evaluated. As 
part of his PhD, X wants to gather feedback on the perceptions and challenges experienced by HCPs 
resulting from the GMS co-payment changes. For example, are co-payment changes creating 
additional administrative burden for HCPs? Have altering co-payments influenced GPs’ prescribing 
patterns? How have pharmacists handled the implementation of this policy? What happens if patients 
cannot afford these prescription medicine co-payments? This study seeks to retrieve qualitative data 
on HCP stakeholder involvement for all existing co-payment alterations in the Irish context. 
Why have you been asked to participate? 
You have been asked because you are a Healthcare Professional currently working in a GP practice or 
a community pharmacy in the Republic of Ireland.  
What will your participation involve? 
Your participation will involve a 30-minute (maximum) interview about matters relating to your 








pharmacist, will ask questions as the session progress. A small amount of extra time will be allowed 
for explaining the aims of the study and your questions about the study.  
Will your participation be kept confidential? 
Yes, all information will be treated in a confidential manner and your participation is anonymous. The 
interview will be audio recorded so that it can be transcribed afterwards. Your name will not be 
recorded on any information which is collected about you. Instead you will be provided with a unique 
code. The only person with access to the code will be X. The results of the study will be included in X’s 
PhD thesis but there will be no way of identifying you from these results. The results will be seen by 
X’s supervisors, a second marker and an external examiner, again these will be anonymous. The thesis 
may be read by future students. The study may be presented at scientific conferences and/or 
published in an academic journal.  
The audio recording will be erased once the interview has been transcribed. Transcripts will be stored 
in a protected manner for 5 years, after which they will be destroyed in line with University College X 
confidential waste destruction guidelines. 
What are the possible benefits of participating? 
Your contribution to this study will be used to reveal how HCPs have previously dealt and are currently 
dealing with these GMS co-payment policy changes since its inception in 2010. X hopes to publish such 
findings that may influence future healthcare policymaking decisions to the benefit of the HCP and 
patient. 
Are there any risks of participation? 
We do not think that participation in this study will have any negative effect on you.  
Further information 
Approval has been granted to do this study by the Clinical Research Ethics Committee of the Cork 
Teaching Hospitals.  
If you would like a copy of the results, please let X know. 
If you need any further information, do not hesitate to contact the primary researcher, X, by telephone 
X or by email to X or email the supervisor of the project, Professor Y by Y (Telephone:Y). 
Thank you for taking the time to read this information sheet. If you agree to take part in the study, 
please sign the consent form overleaf.  
 
Kind Regards,  
X 









Pharmacist Topic Guide 
Interviewing practising Irish primary healthcare professionals about their opinions, perceptions, 
challenges and experience of the GMS co-payment from inception to current day. 
Before we start, I just want to check that you are still happy for this interview to be recorded and 
that you know we can stop at any time.  
 
I would like to thank you for agreeing to participate in this interview and stress that everything said 
here today is completely confidential. Your name will not appear on any documents or recording 
discs and I personally will anonymise the transcript from this interview, and will ensure that no one 
else will be identifiable either.  
 
These interviews are part of a study I am conducting for my PhD. The aim of the study is to gain an 
understanding of the perceptions and challenges experienced by healthcare professionals from the 
various GMS co-payment iterations since 2010. 
 
There are no right or no wrong answers to these questions. 
The interview will probably last between 10-30 minutes.  




• Address of Pharmacy? Independent or Franchise Pharmacy? 
• Gender? 
• Number of years practising in community Pharmacy? 
• Full-time/Part-time? 
• Year received pharmaceutical society of Ireland (PSI) number? 
• Do you have any obvious biases to declare on this topic? 
In Supplementary material Figure 1 presented to you in the information leaflet, you can see the GMS 
co-payment has undergone various iterations since its initial introduction in 2010. As you have been 
practising throughout these changes, I am interested to learn about your experiences in considering 
these policy changes in your routine clinical practice.  
Version 4  
 
1) What are your own thoughts on the GMS co-payment attached to prescription medicines? 
 
• Positive aspects/negative aspects? 
• Do you know why it was initially brought in and its impact to date? 








2) How have co-payments influenced your practice and procedures in the Pharmacy, if at all? 
• Have they changed the way you and the Pharmacy staff work, if so, how? 
3) How easy or difficult is it to retrieve co-payments from patients?  
• What happens if a patient cannot pay? Do you supply the medicine anyway? 
• Have you a procedure in place for patients who cannot pay? 
• Have you encountered awkward situations when a patient cannot pay? 
• Have you suffered financial loss because of patients not paying? 
4) In your opinion, have co-payments presented an administrative burden to you/your practice?  
• Have you noticed/recommended eligible patients to switch to the long-term illness (LTI) 
scheme to avoid paying the co-payment?  
5) How do you think GMS patients perceive paying the co-payment attached to their prescription 
medicines? 
• Do you think the co-payments are reasonably or unfairly priced for GMS patients?  
6) Do you think co-payments have influenced patients’ utilisation of medicines?  
• Increase/decrease in patients picking up their medicines?  
• Are there particular types of medicines affected more by the GMS co-payment changes? 
7) Looking at Figure 1, would you have regarded any one of these GMS co-payment changes to be 
more influential or impactful than the others? 
• Effect on patient picking up medication 
• More difficult to retrieve the co-payment from the patient upon being increased? 
8) Have you noticed any changes to the prescribing patterns of physicians since the introduction and 
changes in the GMS co-payment?  
• Any issues/concerns arising from GPs concerning GMS co-payments?  
• An increase in generic prescribing since the beginning of the co-payment? 
9) What do you think the future holds for the GMS co-payment?  
• Should the co-payment be increased, decreased or abolished? 
• Do you think the previous GMS co-payment changes were evidence-based? 
• How should Pharmacists/representative bodies be involved in this policy, if it all?  
 









General Practitioner (GP) Topic Guide 
Interviewing practising Irish primary healthcare professionals about their opinions, perceptions and 
experience of the GMS co-payment from inception to current day 
Before we start, I just want to check that you are still happy for this interview to be recorded and 
that you know we can stop at any time.  
 
I would like to thank you for agreeing to participate in this interview and stress that everything said 
here today is completely confidential. Your name will not appear on any documents or recording 
discs and I personally will anonymise the transcript from this interview, and will ensure that no one 
else will be identifiable either.  
 
There will not be any consequences to what you tell me and there will be no blame attributed to you 
or anyone else.  
 
These interviews are part of my PhD There are no right or no wrong answers to these questions, just 
give as much detail as you can. It will probably last between 10-30 minutes.  




• Address of GP practice? Independent or medical centre practice? 
• Gender? 
• Number of years practising as a GP? 
• Full-time/Part-time? 
• Year received Irish medical council (IMC) number? 
• Do you have any obvious biases to declare on this topic? 
 
In Supplementary material Figure 1 presented to you in the information leaflet, you can see the GMS 
co-payment has undergone various iterations since its initial introduction in 2010. As you have been 
practising throughout these changes, please answer the following questions with respect to this. 
Version 2  
1) What are your own thoughts on the GMS prescription medicine co-payments? 
• Positive aspects/negative aspects? 
• Do you know why it was initially brought in and its impact to date? 











2) How have co-payments influenced your practice and procedures as a GP, if it all? 
• Have they changed the way you prescribe, if so, how? 
• Have they influenced the amount of prescriptions you issue, if so, how? 
• What happens if you know a patient cannot pay? Do you still prescribe the medicine? 
• Have you noticed/recommended eligible patients to switch to the long-term illness (LTI) 
scheme to avoid paying the GMS co-payment? 
 
3) How do you think GMS patients perceive paying the co-payment attached to their prescription 
medicines? 
• Do you think the co-payments are reasonably or unfairly priced for GMS patients?  
4) In your opinion, are GMS co-payments effective at preventing patients from collecting medicines 
they actually do not require? 
• Yes/no – Why? 
5) In what way, if any, do you think co-payments have influenced patients’ utilisation of medicines?  
• An increase in patients asking you to prescribe/deprescribe certain medicines 
• A decrease in patients asking you to prescribe/deprescribe certain medicines 
 
6) In your opinion, are there particular types of medicines affected more by the GMS co-payment 
changes? 
7) Looking at Figure 1, would you have regarded any one of these GMS co-payment changes to be 
more influential or impactful than the others? 
• Effect of patient asking you to presecribe/deprescribe certain medicines 
• Patient expressing concern to you on co-payment changes 
 
8) Have you encountered any issues or concerns from patients concerning GMS co-payments that 
they may have experienced when collecting prescription medicines at their pharmacy?  
9) Have you encountered any issues or concerns from pharmacists concerning GMS co-payments 
that they may have experienced when serving patients in the pharmacy? 
10) What do you think the future holds for the GMS co-payment?  
• Should it be increased, decreased or abolished?  
• Do you think the previous GMS co-payment changes were evidence-based? 
• What advice have you for policymakers on it? Should GP representative bodies be involved?          
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Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist [1] 
 
Developed from: 
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-
item checklist for interviews and focus groups. International Journal for Quality in Health Care. 2007. 
Volume 19, Number 6: pp. 349 – 357  
 
YOU MUST PROVIDE A RESPONSE FOR ALL ITEMS. ENTER N/A IF NOT APPLICABLE 
 
No.  Item  
 
Guide questions/description Reported on Page # 
Domain 1: Research team 
and reflexivity  
  
Personal Characteristics    
1. Interviewer/facilitator Which author/s conducted the interview or 
focus group?  
GOB and BOF  
2. Credentials What were the researcher’s credentials? E.g. 









4. Gender Was the researcher male or female?  Male 
5. Experience and training What experience or training did the researcher 
have?  




Group, May 2018, 
University of Oxford 
Relationship with participants    
6. Relationship established Was a relationship established prior to study 
commencement?  
No 
7. Participant knowledge of 
the interviewer  
What did the participants know about the 
researcher? e.g. personal goals, reasons for 
doing the research  
Based on participant 
information letter 
provided 
8. Interviewer characteristics What characteristics were reported about the 
interviewer/facilitator? e.g. Bias, assumptions, 












Domain 2: study design    
Theoretical framework    
9. Methodological orientation 
and Theory  
What methodological orientation was stated 
to underpin the study? e.g. grounded theory, 
discourse analysis, ethnography, 




Participant selection    
10. Sampling How were participants selected? e.g. 




11. Method of approach How were participants approached? e.g. face-
to-face, telephone, mail, email  
Email, phone, face-
to-face 
12. Sample size How many participants were in the study?  19 
13. Non-participation How many people refused to participate or 
dropped out? Reasons?  
0 
Setting   
14. Setting of data collection Where was the data collected? e.g. home, 




15. Presence of non-
participants 
Was anyone else present besides the 
participants and researchers?  
No 
16. Description of sample What are the important characteristics of the 




the introduction of 
the co-payment in 
2010 to end of study 
date 
Data collection    
17. Interview guide Were questions, prompts, guides provided by 
the authors? Was it pilot tested?  
Questions were 
based on the topic 
guides used 
18. Repeat interviews Were repeat interviews carried out? If yes, 
how many?  
N/A 
19. Audio/visual recording Did the research use audio or visual recording 
to collect the data?  
Two methods of 
audio recording 









20. Field notes Were field notes made during and/or after the 
interview or focus group? 
Notes were added 
to a field diary 
immediately after 
the interview 
21. Duration What was the duration of the interviews or 
focus group?  
7 - 30 minutes 
22. Data saturation Was data saturation discussed?  Yes  (Francis 
method[2]) 
23. Transcripts returned Were transcripts returned to participants for 
comment and/or correction?  
Optional if 
participants 
required – choice 
presented on the 
consent form 
Domain 3: analysis and 
findings  
  
Data analysis    
24. Number of data coders How many data coders coded the data?  One primary coder 





25. Description of the coding 
tree 
Did authors provide a description of the coding 
tree?  
Yes 
26. Derivation of themes Were themes identified in advance or derived 
from the data?  
Both deductive and 
inductive themes 
are presented 
27. Software What software, if applicable, was used to 
manage the data?  
NVivo 12 Plus - QSR 
International 
28. Participant checking Did participants provide feedback on the 
findings?  
No 
Reporting    
29. Quotations presented Were participant quotations presented to 
illustrate the themes/findings? Was each 
quotation identified? e.g. participant number  
Yes 
30. Data and findings 
consistent 
Was there consistency between the data 
presented and the findings?  
Yes 
31. Clarity of major themes Were major themes clearly presented in the 
findings?  
Yes 
32. Clarity of minor themes Is there a description of diverse cases or 











1 Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research 
(COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19 (6): 
349-357 DOI 10.1093/intqhc/mzm042 
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What is an adequate sample size? Operationalising data saturation for theory-based 
interview studies. Psychol Health 25  DOI 10.1080/08870440903194015 
 
Key Points:  
Co-payments can result in cost containment, moral hazard prevention and revenue generation. 
Community pharmacists have reported reductions in workplace productivity and direct financial loss. 
General Practitioners want a co-payment policy attached to publically insured patient-physician 
consultations.  
 
 
